Category: Mergers & Acquisitions

HBM Pharma/Biotech M&A and New Drug Approvals Reports 
Posted on Mar 15, 2016

  We’re late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw data for analysis. Below are a few highlights which caught our eye: M&A Activity – By numerous measures, 2015 was a record year, especially in terms

Inversions: Alive or Dead? 
Posted on Oct 09, 2014

  The reports of my death have been greatly exaggerated. Mark Twain In July, we summarized the issue of companies acquiring other companies in tax-friendly countries. These so-called “inversions” were not a new phenomenon, but their interest (at least in our industry) reached a fevered pitch this year. Can This Continue? This was a question we

The Premium of a Big Pharma License Deal 
Posted on Jul 30, 2014

  Source: Nature Biotechnology, 32, 617–619, (2014), Published online 08 July 2014 Our good friends at Venture Valuation published an interesting study in the July issue of Nature Biotechnology. In the study, the authors address an interesting question, namely, do small-to-medium sized enterprises (SMEs) receive more lucrative deals from Big Pharma compared to other SMEs?

If It’s Difficult, Do It 
Posted on Aug 28, 2013

     Today we learn that Endo is acquiring Boca Pharmacal for $225 million: Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include: controlled substances, semisolids, and solutions.  Boca Pharmacal’s commercial footprint and R&D pipeline are a strong complement …Since its beginnings in 1998,

Perrigo Elan: Markets not happy with Papa 
Posted on Aug 06, 2013

    We don’t normally comment on stock activity, but the market response to the Perrigo Elan announcement caught our eye: As was pointed out in The Guardian: Perrigo, which makes over-the-counter medicines and vitamins, said it would make annual savings of more than $150m (£98m) in taxes and operating costs by moving its headquarters

Acquiring Assets from Big Pharma: A How-To Guide 
Posted on Jun 12, 2013

    Ok, we have to admit. This is not exactly a “how to” guide. In fact, writing such a guide may not be possible. But first, let’s dispel the myth that it is impossible to acquire on-market assets from big pharma.     Acquiring Assets from Big Pharma may be difficult, but it is

Biotech Business Development: One more time 
Posted on Jun 06, 2013

    Biotech business development has become more sophisticated and more complex. Yet we see companies running processes which are suboptimal. Here is a case in point. We’re reviewing several presentations for companies looking to out-license their early-stage assets, and they are making the same mistake. They are emphasizing technical and scientific features instead of the

Payday Redux: Deals, Deals, and more Deals 
Posted on Jun 05, 2013

    It’s been difficult to keep up with all the deals this month! We won’t review them all here, as that’s best done by others. But here are a few recent ones which caught our eye:   Elan is making all the headlines lately, with deals with Theravance, AOP Orphan, Newbridge (a very good

Drug Delivery is Alive and Well 
Posted on Jan 23, 2013

The announcement of the Allergan acquisition of MAP Pharmaceuticals for nearly $1 billion (and the NuPathe approval) is a good reminder of the potential value (both clinical and financial) of reformulation and drug delivery approaches to product development. Now there no question that new pharmacologies are needed in just about all therapeutic categories. Unmet needs continue to persist

Predictions for 2013 
Posted on Jan 02, 2013

Happy New Year! For many companies, 2012 was a challenging year. How will 2013 play out? Here are a few ideas we’ve discussed internally as we look forward to 2013: Innovation versus Revenue – Companies (and their investors) talk a lot about innovation. And indeed, innovation is important. However, what companies really really want is

Abandon R&D for M&A? Vote today! 
Posted on Sep 05, 2012

In response to the recent acquisition of Medicis by Valeant, an interesting poll underway asking a seemingly simple question, “Will other pharma companies follow Valeant and abandon R&D in favor of M&A?” If you’d like to vote in the poll, you can find it here. As of this writing, nearly 70% or respondents voted “Yes”

Looking for a job in pharma? Good luck 
Posted on Jul 14, 2011

Today, KPMG is reporting results from a survey of pharmaceutical executives. In this survey, respondents said they will increase their acquisition activity in the coming year in order to gain new therapies and new customers. In the KPMG survey, 83 percent of executives said it is likely their company will be involved in a merger

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.